Catalyst Rx introduces new mobile platform
Catalyst Rx Mobile is an element of Catalyst’s Generic Advantage plan, developed after more than a year of consultation with experts in the areas of pharmacy, behavioral psychology
Exegenesis Bio and Modalis Therapeutics have entered a research partnership and licence agreement to progress MDL-201, a therapeutic candidate for Duchenne muscular dystrophy (DMD).